anti-BCMA, BCMA CAR-T, chimeric antigen receptor T cell therapy, China, Immune thrombocytopenia, ITP
Anti-BCMA CAR T-Cell therapy clinical trials for relapse/refractory Immune thrombocytopenia(R/R ITP)
March 2023: Immune thrombocytopenia (ITP) is a disorder that can lead to easy or excessive bruising and bleeding. Approximately two-thirds of patients achieve remission after/during first-line therapies. However, the other part o..
anti-BCMA, CAR - T Cell therapy, CT103A, FDA, IASO Biotherapeutics, Innovent Biologics, orphan drug designation
CT103A, CAR T-cell Therapy, has been designated as an orphan drug by the FDA
Feb 2023: The FDA has granted orphan drug status to CT103A, an experimental CAR T-cell therapy being developed by IASO Biotherapeutics and Innovent Biologics to treat relapsed or refractory multiple myeloma. Orphan drug d..